Radiosensitization by the mTOR inhibitor RAD001 involves the induction of autophagy in two cancer cell lines

被引：0
|
作者：
Bischoff, Pierre L. [1 ]
Altmeyer, Anais [1 ]
Josset, Elodie [1 ]
Denis, Jean -Marc [2 ]
Gueulette, John [2 ]
Slabbert, Jakobus P. [3 ]
Noel, Georges [1 ]
机构：
[1] Univ Strasbourg, Ctr Paul Strauss, EA 3430, Strasbourg, France
[2] Catholic Univ Louvain, MIRO, B-1200 Brussels, Belgium
[3] iThemba LABS, Somerset West, South Africa
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/1538-7445.AM2012-1466
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1466
引用
收藏
页数：2
相关论文
共 50 条
  • [31] The mTOR inhibitor RAD001 (Everolimus) improves survival in preclinical models of primary human ALL
    Crazzolara, Roman
    Cisterne, Adam
    Thien, Marilyn
    Hewson, John
    Bradstock, Kenneth Francis
    Bendall, Linda J.
    BLOOD, 2007, 110 (11) : 262A - 262A
  • [32] A Phase I Pilot Study of the Oral mTOR Inhibitor RAD001 in Combination with Capecitabine for Metastatic Breast Cancer.
    Chen, C. S.
    Chen, M. M.
    Imaoka, R. T.
    Svahn, T.
    Guardino, A. E.
    CANCER RESEARCH, 2009, 69 (24) : 860S - 860S
  • [33] A Phase 1/2 Study of RAD001, a mTOR Inhibitor, In Patients with Myelofibrosis: Final Results
    Vannucchi, Alessandro M.
    Guglielmelli, Paola
    Lupo, Letizia
    Finazzi, Maria Chiara
    Tozzi, Lorenzo
    Biamonte, Flavia
    Masciulli, Arianna
    Susini, Maria Chiara
    Pancrazzi, Alessandro
    Finazzi, Guido
    Paratore, Simona
    Marchioli, Roberto
    Bosi, Alberto
    Barbui, Tiziano
    Rambaldi, Alessandro
    Barosi, Giovanni
    BLOOD, 2010, 116 (21) : 143 - 143
  • [34] Novel and Evolving Therapies in the Treatment of Malignant Phaeochromocytoma: Experience with the mTOR Inhibitor Everolimus (RAD001)
    Druce, M. R.
    Kaltsas, G. A.
    Fraenkel, M.
    Gross, D. J.
    Grossman, A. B.
    HORMONE AND METABOLIC RESEARCH, 2009, 41 (09) : 697 - 702
  • [35] IN VITRO STUDIES ON RESISTANCE MECHANISM IN PROSTATE CARCINOMA CELLS INDUCED BY THE MTOR INHIBITOR RAD001
    Tsaur, I
    Wedel, S. A.
    Makarevic, J.
    Bartsch, G.
    Haferkamp, A.
    Blaheta, R.
    EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 294 - 294
  • [36] The mTOR (mammalian target of rapamycin) inhibitor RAD001 (Everolimus) is safe and reduces proliferation in postmenopausal women with breast cancer
    Macaskill, E. J.
    Bartlett, J. M. S.
    Renshaw, L.
    Faratian, D.
    White, S.
    Campbell, F. M.
    Young, O.
    Stumm, M.
    Thomas, J.
    Barber, M. D.
    Dixon, J. M.
    EJC SUPPLEMENTS, 2007, 5 (03): : 30 - 30
  • [37] PHASE II STUDY OF MTOR-INHIBITOR RAD001 AND ERLOTINIB FOR ADVANCED, GEMCITABINE-REFRACTORY PANCREATIC CANCER
    Javle, M.
    Reddy, S.
    Varadhachary, G.
    Kaseb, A.
    Fogelman, D.
    Wolff, R.
    Abbruzzese, J.
    PANCREAS, 2008, 37 (04) : 476 - 476
  • [38] Phase II study of MTOR-inhibitor RAD001 and erlotinib for advanced, gemcitabine-refractory pancreatic cancer
    Javle, M.
    Fogelman, D.
    Kaseb, A.
    Varadhachary, G.
    Wolff, R.
    Abbruzzese, J.
    EJC SUPPLEMENTS, 2008, 6 (12): : 104 - 104
  • [39] Combination of carboplatin and the mTor inhibitor RAD001 is a new therapeutic approach for p53-mutated breast cancer
    Lin, H.
    Possinger, K.
    Eucker, J.
    CANCER RESEARCH, 2009, 69 (02) : 93S - 93S
  • [40] The mTOR pathway inhibitor RAD001 (everolimus) is highly efficacious in tamoxifen-sensitive and -resistant breast cancer xenografts
    Diana Behrens
    Anne E. Lykkesfeldt
    Iduna Fichtner
    Targeted Oncology, 2007, 2 : 135 - 144
12345